Altimmune ALT EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Altimmune’s reported figures.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's EBIT?
- Altimmune (ALT) reported EBIT of -$24.24M in Q1 2026.
- How has Altimmune's EBIT changed year-over-year?
- Altimmune's EBIT decreased by 11.1% year-over-year, from -$21.82M to -$24.24M.
- What is the long-term trend for Altimmune's EBIT?
- Over 4 years (2021 to 2025), Altimmune's EBIT has grown at a -0.6% compound annual growth rate (CAGR), from -$96.91M to -$94.49M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.